Milwaukee Business Journal reports Aurora Research Institute has launched two new trials for leukemia patients. It is hoped that this breakthrough will change treatment options for patients with leukemia. Aurora Research Institute’s anticancer drug called ibrutinib is being mobilized for the treating of chronic lymphocytic leukemia (CLL). According to principal investigator Dr. Rubina Quamar, “CLL is the most common leukemia in adults in Western countries.”
Read more about ibrutinib from the source story below. Ibrutinib is owned by AbbVie. Aurora Healthcare is a not-for-profit healthcare system based in Milwaukee, WI. It serves eastern Wisconsin. The system has 15 hospitals with more than 150 clinics and 70 pharmacies. The system includes 32,000 employees including 1,800 employed physicians. Its clinical trials are managed through the Aurora Research Institute.
Dr. Rubina Quamar, Aurora Healthcare